Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle

JCI Insight

Volumn 1, Issue 21, 2016, Pages

  Hammers, David W ^a,b   Sleeper, Margaret M ^b,c,d   Forbes, Sean C ^b,e   Coker, Cora C ^b   Jirousek, Michael R ^f   Zimmer, Michael ^f   Walter, Glenn A ^b   Sweeney, H Lee ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^d University of Florida College of Veterinary Medicine   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f Catabasis Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85134772038     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.90341     Document Type: Article

References (34)

1. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51(6):919-928.
2. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A. 1993; 90(8):3710-3714.
3. Bakkar N, Guttridge DC. NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol Rev. 2010; 90(2):495-511.
4. Marienfeld R, May MJ, Berberich I, Serfling E, Ghosh S, Neumann M. RelB forms transcriptionally inactive complexes with RelA/p65. J Biol Chem. 2003; 278(22):19852-19860.
5. Legarda-Addison D, Ting AT. Negative regulation of TCR signaling by NF-kappaB2/p100. J Immunol. 2007; 178(12):7767-7778.
6. Sasaki CY, Barberi TJ, Ghosh P, Longo DL. Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. J Biol Chem. 2005; 280(41):34538-34547.
7. Pradère JP, Hernandez C, Koppe C, Friedman RA, Luedde T, Schwabe RF. Negative regulation of NF-κB p65 activity by serine 536 phosphorylation. Sci Signal. 2016; 9(442):ra85.
8. Acharyya S, et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest. 2007; 117(4):889-901.
9. Singh R, et al. Increases in nuclear p65 activation in dystrophic skeletal muscle are secondary to increases in the cellular expression of p65 and are not solely produced by increases in IkappaB-alpha kinase activity. J Neurol Sci. 2009; 285(1-2):159-171.
10. Messina S, et al. Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age. Acta Myol. 2011; 30(1):16-23.
11. Monici MC, Aguennouz M, Mazzeo A, Messina C, Vita G. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology. 2003; 60(6):993-997.
12. Tang Y, et al. Inhibition of the IKK/NF-κB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther. 2010; 17(12):1476-1483.
13. Delfín DA, Xu Y, Peterson JM, Guttridge DC, Rafael-Fortney JA, Janssen PM. Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy. J Transl Med. 2011; 9:68.
14. Peterson JM, et al. Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med. 2011; 17(5-6):508-515.
15. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994; 265(5174):956-959.
16. Zwart SR, Pierson D, Mehta S, Gonda S, Smith SM. Capacity of omega-3 fatty acids or eicosapentaenoic acid to counteract weightlessness-induced bone loss by inhibiting NF-kappaB activation: from cells to bed rest to astronauts. J Bone Miner Res. 2010; 25(5):1049-1057.
17. Vu CB, et al. Synthesis and characterization of fatty acid conjugates of niacin and salicylic acid. J Med Chem. 2016; 59(3):1217-1231.
18. De Luca A, et al. Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis. 2008; 32(2):243-253.
19. Smythe GM, White JD. Voluntary wheel running in dystrophin-deficient (mdx) mice: Relationships between exercise parameters and exacerbation of the dystrophic phenotype. PLoS Curr. 2011; 3:RRN1295.
20. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord. 2003; 13(2):166-172.
21. Burkin DJ, Wallace GQ, Nicol KJ, Kaufman DJ, Kaufman SJ. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice. J Cell Biol. 2001; 152(6):1207-1218.
22. Heller KN, Montgomery CL, Janssen PM, Clark KR, Mendell JR, Rodino-Klapac LR. AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice. Mol Ther. 2013; 21(3):520-525.
23. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature. 1996; 384(6607):349-353.
24. Tzeng HP, et al. Dysferlin mediates the cytoprotective effects of TRAF2 following myocardial ischemia reperfusion injury. J Am Heart Assoc. 2014; 3(1):e000662.
25. Redpath GM, et al. Calpain cleavage within dysferlin exon 40a releases a synaptotagmin-like module for membrane repair. Mol Biol Cell. 2014; 25(19):3037-3048.
26. Waddell LB, et al. Dysferlin, annexin A1, and mitsugumin 53 are upregulated in muscular dystrophy and localize to longitudinal tubules of the T-system with stretch. J Neuropathol Exp Neurol. 2011; 70(4):302-313.
27. Fuson K, et al. Alternate splicing of dysferlin C2A confers Ca +-dependent and Ca +-independent binding for membrane repair. Structure. 2014; 22(1):104-115.
28. Barton ER, Wang BJ, Brisson BK, Sweeney HL. Diaphragm displays early and progressive functional deficits in dysferlindeficient mice. Muscle Nerve. 2010; 42(1):22-29.
29. Kornegay JN, et al. NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy. Skelet Muscle. 2014; 4:18.
30. Donovan JM, Zimmer M, Offman E, Grant T, Jirousek MR. A novel NF-κB inhibitor (edasalonexent, CAT-1004) in development as a disease-modifying treatment for patients with Duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects. J Clin Pharmacol. In Press.
31. Millay DP, et al. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol. 2009; 175(5):1817-1823.
32. Glover LE, et al. Dysferlin overexpression in skeletal muscle produces a progressive myopathy. Ann Neurol. 2010; 67(3):384-393.
33. Hammers DW, Sleeper MM, Forbes SC, Shima A, Walter GA, Sweeney HL. Tadalafil treatment delays the onset of cardiomyopathy in dystrophin-deficient hearts. J Am Heart Assoc. 2016; 5(8):8.
34. Morine KJ, Bish LT, Pendrak K, Sleeper MM, Barton ER, Sweeney HL. Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One. 2010; 5(2):e9176